Business Context and Reporting Period
This Form 6-K filing covers the month of June 2011 for Prana Biotechnology Limited (ASX: PBT), a foreign private issuer. The document reports the results of the company's 2011 General Meeting held on June 10, 2011. Note: The metadata references "Alterity Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
All resolutions presented at the General Meeting were unanimously carried on a show of hands. The detailed voting results for the four resolutions were as follows:
- Resolution 1a (Approval of Prior Issue of Securities – Private Placement): 33,455,099 For; 2,142,960 Against; 663,400 Abstain; 18,936,967 Proxy Discretion; Total 55,198,426.
- Resolution 1b (Approval of Prior Issue of Securities – Rodman & Renshaw LLC): 33,493,319 For; 2,104,740 Against; 663,400 Abstain; 18,936,967 Proxy Discretion; Total 55,198,426.
- Resolution 2 (Share Placement – No. 1): 33,290,399 For; 2,257,660 Against; 673,400 Abstain; 18,976,967 Proxy Discretion; Total 55,198,426.
- Resolution 3 (Share Placement – No. 2): 33,282,659 For; 2,265,400 Against; 673,400 Abstain; 18,976,967 Proxy Discretion; Total 55,198,426.
The Chairman voted undirected proxies in his control in favor of all resolutions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document serves solely as a record of the shareholder meeting outcomes.
Key Facts for Investor Verification
- Confirm the identity of the registrant as Prana Biotechnology Limited, distinct from the metadata label "Alterity Therapeutics Ltd."
- Verify the successful approval of prior security issues via private placement and through Rodman & Renshaw LLC.
- Note the high volume of proxy discretion votes (approx. 18.9 million) relative to direct "For" votes, indicating significant reliance on proxy voting mechanisms.
- Check subsequent filings for financial details regarding the share placements approved in this meeting, as no financial impact is quantified here.